{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:15:25Z","timestamp":1773015325013,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"crossref","award":["H29-Nanchitou (Nan)-Ippan-043"],"award-info":[{"award-number":["H29-Nanchitou (Nan)-Ippan-043"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["Practical Research Project for Rare\/Intractable Diseases"],"award-info":[{"award-number":["Practical Research Project for Rare\/Intractable Diseases"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Multiple Sclerosis Society","award":["none"],"award-info":[{"award-number":["none"]}]},{"name":"Japan Intractable Disease Research Foundation"},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["MEXT KAKENHI Grant Number 25117012"],"award-info":[{"award-number":["MEXT KAKENHI Grant Number 25117012"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JSPS KAKENHI Grant Number 16H02657"],"award-info":[{"award-number":["JSPS KAKENHI Grant Number 16H02657"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JSPS KAKENHI Grant Numbers 16K09694"],"award-info":[{"award-number":["JSPS KAKENHI Grant Numbers 16K09694"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JSPS KAKENHI Grant Number 15K09341"],"award-info":[{"award-number":["JSPS KAKENHI Grant Number 15K09341"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JSPS KAKENHI Grant Number 17K16125"],"award-info":[{"award-number":["JSPS KAKENHI Grant Number 17K16125"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12974-018-1295-1","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T12:20:01Z","timestamp":1536150001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression"],"prefix":"10.1186","volume":"15","author":[{"given":"Yuri","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gaetano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altermatt","family":"Anna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst-Wilhelm","family":"Radue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wuerfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Saida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/archneur.1962.04210020005001","volume":"7","author":"M Alter","year":"1962","unstructured":"Alter M. Multiple sclerosis in the Negro. Arch Neurol. 1962;7:83\u201391.","journal-title":"Arch Neurol"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1212\/01.WNL.0000145762.60562.5D","volume":"63","author":"BAC Cree","year":"2004","unstructured":"Cree BAC, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63:2039\u201345.","journal-title":"Neurology"},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","volume":"75","author":"I Kister","year":"2010","unstructured":"Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75:217\u201323.","journal-title":"Neurology"},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00415-015-7637-3","volume":"262","author":"L Piccolo","year":"2015","unstructured":"Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, et al. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol. 2015;262:831\u20136.","journal-title":"J Neurol"},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","volume":"120","author":"F Barkhof","year":"1997","unstructured":"Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059\u201369.","journal-title":"Brain"},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2009.01.008","volume":"280","author":"T Ishizu","year":"2009","unstructured":"Ishizu T, Kira J, Osoegawa M, Fukazawa T, Kikuchi S, Fujihara K, et al. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neurol Sci. 2009;280:22\u20138.","journal-title":"J Neurol Sci"},{"key":"1295_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175279","volume":"12","author":"RM Gie\u00df","year":"2017","unstructured":"Gie\u00df RM, Pfuhl C, Behrens JR, Rasche L, Freitag E, Khalighy N, et al. Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS One. 2017;12:e0175279.","journal-title":"PLoS One"},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ana.10551","volume":"53","author":"F Barkhof","year":"2003","unstructured":"Barkhof F, Rocca M, Francis G, Van Waesberghe J-HTM, Uitdehaag BMJ, Hommes OR, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol. 2003;53:718\u201324.","journal-title":"Ann Neurol"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/jnnp.67.2.153","volume":"67","author":"I Nakashima","year":"1999","unstructured":"Nakashima I, Fujihara K, Okita N, Takase S, Itoyama Y. Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;67:153\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/1352458517707067","volume":"24","author":"K Shinoda","year":"2018","unstructured":"Shinoda K, Matsushita T, Nakamura Y, Masaki K, Yamasaki R, Yamaguchi H, et al. HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Mult Scler. 2018;24:710\u201320.","journal-title":"Mult Scler"},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302. \n                    https:\/\/doi.org\/10.1002\/ana.22366\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/jnnp.2005.073247","volume":"77","author":"JK Swanton","year":"2006","unstructured":"Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006;77:830\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/jnnp.2008.169045","volume":"80","author":"CC Lo","year":"2009","unstructured":"Lo CC, Kao HH, Chen SS, Hsueh CC, Lin WW, Hsu WW, et al. Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria. J Neurol Neurosurg Psychiatry. 2009;80:1107\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124\u201340.","journal-title":"N Engl J Med"},{"key":"1295_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1177\/1352458511435984","volume":"18","author":"T Saida","year":"2012","unstructured":"Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler. 2012;18:1269\u201377.","journal-title":"Mult Scler"},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352.","journal-title":"Neurology"},{"key":"1295_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hbm.10062","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143\u201355.","journal-title":"Hum Brain Mapp"},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17:479\u201389.","journal-title":"NeuroImage"},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56:907\u201322.","journal-title":"NeuroImage"},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/brain\/awh714","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595\u2013605.","journal-title":"Brain"},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1212\/WNL.0b013e318230a17d","volume":"77","author":"A Scalfari","year":"2011","unstructured":"Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77:1246\u201352.","journal-title":"Neurology"},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/WNL.55.10.1506","volume":"55","author":"GRW Moore","year":"2000","unstructured":"Moore GRW, Leung E, MacKay AL, Vavasour IM, Whittall KP, Cover KS, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology. 2000;55:1506\u201310.","journal-title":"Neurology"},{"key":"1295_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ana.21113","volume":"62","author":"E Fisher","year":"2007","unstructured":"Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol. 2007;62:219\u201328.","journal-title":"Ann Neurol"},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1474-4422(06)70349-0","volume":"5","author":"RA Bermel","year":"2006","unstructured":"Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158\u201370.","journal-title":"Lancet Neurol"},{"key":"1295_CR25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1212\/01.wnl.0000210506.00078.5c","volume":"66","author":"DK Li","year":"2006","unstructured":"Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66:1384\u20139.","journal-title":"Neurology"},{"key":"1295_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/brain\/awm329","volume":"131","author":"LK Fisniku","year":"2008","unstructured":"Fisniku LK, Brex PAP, Altmann DRDR, Miszkiel KA, Benton CEC, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808\u201317.","journal-title":"Brain"},{"key":"1295_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.25150","volume":"83","author":"CJ Azevedo","year":"2018","unstructured":"Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, et al. Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018;83:223\u201334.","journal-title":"Ann Neurol"},{"key":"1295_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1586\/14737175.6.3.357","volume":"6","author":"R Bergamaschi","year":"2006","unstructured":"Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother. 2006;6:357\u201364.","journal-title":"Expert Rev Neurother"},{"key":"1295_CR29","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00415-012-6475-9","volume":"259","author":"K Hackmack","year":"2012","unstructured":"Hackmack K, Weygandt M, Wuerfel J, Pfueller CF, Bellmann-Strobl J, Paul F, et al. Can we overcome the \u201cclinico-radiological paradox\u201d in multiple sclerosis? J Neurol. 2012;259:2151\u201360.","journal-title":"J Neurol"},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.neuroscience.2015.07.006","volume":"303","author":"CE van Munster","year":"2015","unstructured":"van Munster CE, Jonkman LE, Weinstein HC, Uitdehaag BM, Geurts JJ. Gray matter damage in multiple sclerosis: impact on clinical symptoms. Neuroscience. 2015;303:446\u201361.","journal-title":"Neuroscience"},{"key":"1295_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12974-016-0695-3","volume":"13","author":"Y Nakamura","year":"2016","unstructured":"Nakamura Y, Matsushita T, Sato S, Niino M, Fukazawa T, Yoshimura S, et al. Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study. J Neuroinflammation. 2016;13:239.","journal-title":"J Neuroinflammation"},{"key":"1295_CR32","doi-asserted-by":"publisher","first-page":"e48592","DOI":"10.1371\/journal.pone.0048592","volume":"7","author":"S Yoshimura","year":"2012","unstructured":"Yoshimura S, Isobe N, Yonekawa T, Matsushita T, Masaki K, Sato S, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One. 2012;7:e48592.","journal-title":"PLoS One"},{"key":"1295_CR33","doi-asserted-by":"publisher","first-page":"e69919","DOI":"10.1371\/journal.pone.0069919","volume":"8","author":"Y-C Kuan","year":"2013","unstructured":"Kuan Y-C, Wang K-C, Yuan W-H, Tsai C-P. Tumefactive multiple sclerosis in Taiwan. PLoS One. 2013;8:e69919.","journal-title":"PLoS One"},{"key":"1295_CR34","unstructured":"Poser S, L\u00fcer W, Bruhn H, Frahm J, Br\u00fcck Y, Felgenhauer K. Acute demyelinating disease. Classification and non-invasive diagnosis Acta Neurol. Scandinavica 1992;86:579\u2013585."},{"key":"1295_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jns.2017.08.005","volume":"381","author":"P S\u00e1nchez","year":"2017","unstructured":"S\u00e1nchez P, Meca-Lallana V, Barbosa A, Manzanares R, Palm\u00ed I, Vivancos J. Tumefactive demyelinating lesions of 15 patients: clinico-radiological features, management and review of the literature. J Neurol Sci. 2017;381:32\u20138.","journal-title":"J Neurol Sci"},{"key":"1295_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/1352458516641776","volume":"22","author":"TA Hardy","year":"2016","unstructured":"Hardy TA, Tobin WO, Lucchinetti CF. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Bal\u00f3\u2019s concentric sclerosis. Mult Scler J. 2016;22:986\u201392.","journal-title":"Mult Scler J"},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00415-009-5108-4","volume":"256","author":"B Grassiot","year":"2009","unstructured":"Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol. 2009;256:1397\u2013412.","journal-title":"J Neurol"},{"key":"1295_CR38","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1212\/01.WNL.0000036271.49066.06","volume":"59","author":"E Fisher","year":"2002","unstructured":"Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee J-C, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412\u201320.","journal-title":"Neurology"},{"key":"1295_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.msard.2014.07.003","volume":"3","author":"AH Maghzi","year":"2014","unstructured":"Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, et al. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014;3:720\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"1295_CR40","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/01.wnl.0000168837.87351.1f","volume":"65","author":"G Tedeschi","year":"2005","unstructured":"Tedeschi G, Lavorgna L, Russo P, Prinster A, Dinacci D, Savettieri G, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology. 2005;65:280\u20135.","journal-title":"Neurology"},{"key":"1295_CR41","doi-asserted-by":"crossref","unstructured":"Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, et al. Differential impact of multiple sclerosis on cortical and deep gray matter structures in African Americans and Caucasian Americans. J Neuroimaging. 2017;27:333\u20138.","DOI":"10.1111\/jon.12393"},{"key":"1295_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.neuroimage.2010.03.004","volume":"51","author":"A Giorgio","year":"2010","unstructured":"Giorgio A, Santelli L, Tomassini V, Bosnell R, Smith S, De Stefano N, et al. Age-related changes in grey and white matter structure throughout adulthood. NeuroImage. 2010;51:943\u201351.","journal-title":"NeuroImage"},{"key":"1295_CR43","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/cercor\/bhr013","volume":"21","author":"LT Eyler","year":"2011","unstructured":"Eyler LT, Prom-Wormley E, Panizzon MS, Kaup AR, Fennema-Notestine C, Neale MC, et al. Genetic and environmental contributions to regional cortical surface area in humans: a magnetic resonance imaging twin study. Cereb Cortex. 2011;21:2313\u201321.","journal-title":"Cereb Cortex"},{"key":"1295_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2014-308021","volume":"86","author":"C Lukas","year":"2015","unstructured":"Lukas C, Knol DL, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:410\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-018-1295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-018-1295-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-018-1295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:06:21Z","timestamp":1589526381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-018-1295-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1186\/s12974-018-1295-1","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received ethical approval from the Kyushu University Hospital Ethics Committee (approval number 29\u2013173), and written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YN, AA, LB, and MA declare that they have no competing interests. LG reports personal fees from Novartis AG. TM received a grant and payment from Bayer Schering Pharma and Takeda Pharmaceutical Company for manuscript preparation and for development of educational presentations, and also received speaker honoraria payments from Mitsubishi Tanabe Pharma, Bayer Schering Pharma, and Biogen Idec Japan. Till S received previous and\/or current payments for consulting, speaking activities (Actelion, Biogen Idec, Electrocore, Sanofi Genzyme, Mitsubishi Pharma, Teva, Novartis), and grants (EFIC-Gr\u00fcnenthal, Novartis Pharmaceuticals Switzerland, Swiss MS Society, Swiss National Research Foundation). EWR received speaker honoraria and travel compensation from Bayer Schering, Biogen, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, MorphoSys, and Synthon; consulted for Bayer Schering, Biogen Idec, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, Synthon, and MorphoSys; and received institutional research support from Novartis, Biogen Idec, Actelion, Basilea, SAKK, and Synarc. JW is CEO of MIAC AG. He served on scientific advisory board for Actelion, Genzyme, Novartis, Teva, and Roche; he received travel support and\/or speaker honoraria from Bayer, Biogen, and Novartis; he received research support from the EU (Horizon2020), the German Ministry of Education and Research and the German Ministry of Economy. KS has received grants from the Japan Intractable Disease Research Foundation, Japanese Multiple Sclerosis Society, and the Japan Society for the Promotion of Science; and received personal fees from Takeda Pharmaceutical Company and Biogen Japan. NI has received grants and personal fees from Tanabe Mitsubishi Pharma, Bayer Yakuhin, Ltd., and Japan Blood Products Organization. RY has received grants from the Japan Society for the Promotion of Science, Bayer Schering Pharma, Biogen Idec Japan, Novartis Pharma, and Mitsubishi Tanabe Pharma; and received research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labour, and Welfare, Japan. Takahiko S has received funding from, held board membership of, spoken at scientific meetings for, prepared manuscripts for, and had consulting agreements with Astellas Pharma, Bayer Schering, Biogen Japan, Daiichi Sankyo, Eisai, Kaketsuken, Merck Serono, Mitsubishi Tanabe Pharma, Nihon Pharmaceutical, Novartis Pharma, Ono Pharmaceutical, Sanofi, TDS Japan, and Teijin. LK\u2019s Institution (University Hospital Basel) received exclusive research support at the Department of Neurology, including steering committee, advisory board, and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, df-mp, Excemed, GeNeuro SA, Genzyme, Merck, Mitsubishi Pharma, Novartis, Receptos, Roche, Sanofi-Aventis, Santhera, Teva, and Vianex, and royalties from Neurostatus products. For educational activities of the Department, the institution received honoraria from Allergan, Almirall, Bayer, Biogen, Excemed, Genzyme, Merck, Novartis, Pfizer, Sanofi-Aventis, Teva, and UCB. LK has served as principal investigator for the following drug studies: BOLD EXT, EXPAND (BAF312, Novartis), DECIDE, DECIDE EXT (Daclizumab HYP, Biogen), ENDORSE (BG00012, Biogen), FINGORETT, FTYUMBRELLA, INFORMS, INFORMS EXT LONGTERM (Fingolimod, Novartis), MOMENTUM (Amiselimod, Mitsubishi) OCRELIZUMAB PHASE II EXT, OPERA, ORATORIO (Ocrelizumab, Roche), REFLEXION (IFN \u03b2-1a, Merck), STRATA EXT (Natalizumab, Biogen Idec), and TERIFLUNOMIDE EXT (Teriflunomide, Sanofi-Aventis). Research at the MS center in Basel was supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union, and Roche Research Foundations. The institution has also received grants for patient services from Bayer, Merck, and Teva. JK has received grants from the Ministry of Health, Labour, and Welfare, Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, AMED, Japan; and received grants and personal fees from Biogen Idec Japan, Bayer Healthcare, Novartis Pharma, and Mitsubishi Tanabe Pharma, Eisai, Sanofi, Nobelpharma, Otsuka Pharmaceutical, Chugai Pharmaceutical Company, and Teijin Pharma. This independent academic research was supported by Novartis Pharma A.G., Novartis Pharma K.K., and Mitsubishi Tanabe Pharma Corporation, who provided baseline demographic data for the patients analyzed. Novartis and Mitsubishi Tanabe Pharma Corporation played no role in the design, methods, data management, or analysis of the study, or in the decision to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"255"}}